29https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&WebEnv=MCID_600afc5a9a76eb6ec571f0be&query_key=1&retmode=xml&retstart=0&retmax=20&tool=PubFacts&email=info@pubfacts.com&api_key=cff79fa78dbf3b485398a7005ab1d5a49508 Thomas C Harding | PubFacts

Publications by authors named "Thomas C Harding"

20Publications

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.

Authors:
Goldie Y L Lui Reid Shaw Franz X Schaub Isabella N Stork Kay E Gurley Caroline Bridgwater Robert L Diaz Rachele Rosati Hallie A Swan Tan A Ince Thomas C Harding Vijayakrishna K Gadi Barbara A Goff Christopher J Kemp Elizabeth M Swisher Carla Grandori

EBioMedicine 2020 Oct 11;60:102988. Epub 2020 Sep 11.

SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA. Electronic address:

View Article and Find Full Text PDF
October 2020

Evaluation of absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor.

Authors:
Mingxiang Liao Sarah Jaw-Tsai Jeri Beltman Andrew D Simmons Thomas C Harding Jim J Xiao

Xenobiotica 2020 Sep 18;50(9):1032-1042. Epub 2020 Mar 18.

Clovis Oncology, Inc., Boulder, CO, USA.

View Article and Find Full Text PDF
September 2020

Genomic loss of heterozygosity and survival in the REAL3 trial.

Authors:
Elizabeth C Smyth Catherine Cafferkey Andrea Loehr Tom Waddell Ruwaida Begum Clare Peckitt Thomas C Harding Minh Nguyen Alicia F Okines Mitch Raponi Sheela Rao David Watkins Naureen Starling Gary W Middleton Jonathan Wadsley Wasat Mansoor Tom Crosby Andrew Wotherspoon Ian Chau David Cunningham

Oncotarget 2018 Nov 30;9(94):36654-36665. Epub 2018 Nov 30.

Department of Gastrointestinal Oncology and Lymphoma, Royal Marsden Hospital, London & Sutton, United Kingdom.

View Article and Find Full Text PDF
November 2018

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Authors:
Khyati N Shah Roma Bhatt Julia Rotow Julia Rohrberg Victor Olivas Victoria E Wang Golzar Hemmati Maria M Martins Ashley Maynard Jonathan Kuhn Jacqueline Galeas Hayley J Donnella Swati Kaushik Angel Ku Sophie Dumont Gregor Krings Henry J Haringsma Liliane Robillard Andrew D Simmons Thomas C Harding Frank McCormick Andrei Goga Collin M Blakely Trever G Bivona Sourav Bandyopadhyay

Nat Med 2019 01 26;25(1):111-118. Epub 2018 Nov 26.

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.

View Article and Find Full Text PDF
January 2019

Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Authors:
Kevin K Lin Maria I Harrell Amit M Oza Ana Oaknin Isabelle Ray-Coquard Anna V Tinker Elena Helman Marc R Radke Carmen Say Lan-Thanh Vo Elaina Mann Jeffrey D Isaacson Lara Maloney David M O'Malley Setsuko K Chambers Scott H Kaufmann Clare L Scott Gottfried E Konecny Robert L Coleman James X Sun Heidi Giordano James D Brenton Thomas C Harding Iain A McNeish Elizabeth M Swisher

Cancer Discov 2019 02 13;9(2):210-219. Epub 2018 Nov 13.

Division of Gynecologic Oncology, University of Washington, Seattle, Washington.

View Article and Find Full Text PDF
February 2019

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.

Authors:
Elena Helman Minh Nguyen Chris A Karlovich Darrin Despain A Karin Choquette Alexander I Spira Helena A Yu D Ross Camidge Thomas C Harding Richard B Lanman Andrew D Simmons

Clin Lung Cancer 2018 11 7;19(6):518-530.e7. Epub 2018 Aug 7.

Clovis Oncology Inc, Boulder, CO.

View Article and Find Full Text PDF
November 2018

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Authors:
Olga Kondrashova Monique Topp Ksenija Nesic Elizabeth Lieschke Gwo-Yaw Ho Maria I Harrell Giada V Zapparoli Alison Hadley Robert Holian Emma Boehm Valerie Heong Elaine Sanij Richard B Pearson John J Krais Neil Johnson Orla McNally Sumitra Ananda Kathryn Alsop Karla J Hutt Scott H Kaufmann Kevin K Lin Thomas C Harding Nadia Traficante Anna deFazio Iain A McNeish David D Bowtell Elizabeth M Swisher Alexander Dobrovic Matthew J Wakefield Clare L Scott

Nat Commun 2018 09 28;9(1):3970. Epub 2018 Sep 28.

The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia.

View Article and Find Full Text PDF
September 2018

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.

Authors:
Hsien-Ming Hu Xin Zhao Swati Kaushik Lilliane Robillard Antoine Barthelet Kevin K Lin Khyati N Shah Andy D Simmons Mitch Raponi Thomas C Harding Sourav Bandyopadhyay

Cell Rep 2018 Apr;23(3):918-929

Bioengineering and Therapeutic Sciences, Helen Diller Family Comprehensive Cancer Center and Institute for Computational Health Sciences. University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article and Find Full Text PDF
April 2018

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:
Robert L Coleman Amit M Oza Domenica Lorusso Carol Aghajanian Ana Oaknin Andrew Dean Nicoletta Colombo Johanne I Weberpals Andrew Clamp Giovanni Scambia Alexandra Leary Robert W Holloway Margarita Amenedo Gancedo Peter C Fong Jeffrey C Goh David M O'Malley Deborah K Armstrong Jesus Garcia-Donas Elizabeth M Swisher Anne Floquet Gottfried E Konecny Iain A McNeish Clare L Scott Terri Cameron Lara Maloney Jeff Isaacson Sandra Goble Caroline Grace Thomas C Harding Mitch Raponi James Sun Kevin K Lin Heidi Giordano Jonathan A Ledermann

Lancet 2017 Oct 12;390(10106):1949-1961. Epub 2017 Sep 12.

University College London Cancer Institute and University College London Hospitals, London, UK.

View Article and Find Full Text PDF
October 2017

Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Authors:
Olga Kondrashova Minh Nguyen Kristy Shield-Artin Anna V Tinker Nelson N H Teng Maria I Harrell Michael J Kuiper Gwo-Yaw Ho Holly Barker Maria Jasin Rohit Prakash Elizabeth M Kass Meghan R Sullivan Gregory J Brunette Kara A Bernstein Robert L Coleman Anne Floquet Michael Friedlander Ganessan Kichenadasse David M O'Malley Amit Oza James Sun Liliane Robillard Lara Maloney David Bowtell Heidi Giordano Matthew J Wakefield Scott H Kaufmann Andrew D Simmons Thomas C Harding Mitch Raponi Iain A McNeish Elizabeth M Swisher Kevin K Lin Clare L Scott

Cancer Discov 2017 09 6;7(9):984-998. Epub 2017 Jun 6.

Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.

View Article and Find Full Text PDF
September 2017

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Authors:
Elizabeth M Swisher Kevin K Lin Amit M Oza Clare L Scott Heidi Giordano James Sun Gottfried E Konecny Robert L Coleman Anna V Tinker David M O'Malley Rebecca S Kristeleit Ling Ma Katherine M Bell-McGuinn James D Brenton Janiel M Cragun Ana Oaknin Isabelle Ray-Coquard Maria I Harrell Elaina Mann Scott H Kaufmann Anne Floquet Alexandra Leary Thomas C Harding Sandra Goble Lara Maloney Jeff Isaacson Andrew R Allen Lindsey Rolfe Roman Yelensky Mitch Raponi Iain A McNeish

Lancet Oncol 2017 01 29;18(1):75-87. Epub 2016 Nov 29.

Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.

View Article and Find Full Text PDF
January 2017

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Authors:
Jacob J Chabon Andrew D Simmons Alexander F Lovejoy Mohammad S Esfahani Aaron M Newman Henry J Haringsma David M Kurtz Henning Stehr Florian Scherer Chris A Karlovich Thomas C Harding Kathleen A Durkin Gregory A Otterson W Thomas Purcell D Ross Camidge Jonathan W Goldman Lecia V Sequist Zofia Piotrowska Heather A Wakelee Joel W Neal Ash A Alizadeh Maximilian Diehn

Nat Commun 2016 11 14;7:13513. Epub 2016 Nov 14.

View Article and Find Full Text PDF
November 2016

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Authors:
Jacob J Chabon Andrew D Simmons Alexander F Lovejoy Mohammad S Esfahani Aaron M Newman Henry J Haringsma David M Kurtz Henning Stehr Florian Scherer Chris A Karlovich Thomas C Harding Kathleen A Durkin Gregory A Otterson W Thomas Purcell D Ross Camidge Jonathan W Goldman Lecia V Sequist Zofia Piotrowska Heather A Wakelee Joel W Neal Ash A Alizadeh Maximilian Diehn

Nat Commun 2016 06 10;7:11815. Epub 2016 Jun 10.

Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California 94305, USA.

View Article and Find Full Text PDF
June 2016

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.

Authors:
Robert Tjin Tham Sjin Kwangho Lee Annette O Walter Aleksandr Dubrovskiy Michael Sheets Thia St Martin Matthew T Labenski Zhendong Zhu Richland Tester Russell Karp Aravind Medikonda Prasoon Chaturvedi Yixuan Ren Henry Haringsma Jeff Etter Mitch Raponi Andrew D Simmons Thomas C Harding Deqiang Niu Mariana Nacht William F Westlin Russell C Petter Andrew Allen Juswinder Singh

Mol Cancer Ther 2014 Jun 10;13(6):1468-79. Epub 2014 Apr 10.

Authors' Affiliations: Celgene Avilomics Research, Bedford, Massachusetts; and Clovis Oncology Inc., San Francisco, California.

View Article and Find Full Text PDF
June 2014

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

Authors:
Annette O Walter Robert Tjin Tham Sjin Henry J Haringsma Kadoaki Ohashi Jing Sun Kwangho Lee Aleksandr Dubrovskiy Matthew Labenski Zhendong Zhu Zhigang Wang Michael Sheets Thia St Martin Russell Karp Dan van Kalken Prasoon Chaturvedi Deqiang Niu Mariana Nacht Russell C Petter William Westlin Kevin Lin Sarah Jaw-Tsai Mitch Raponi Terry Van Dyke Jeff Etter Zoe Weaver William Pao Juswinder Singh Andrew D Simmons Thomas C Harding Andrew Allen

Cancer Discov 2013 Dec 24;3(12):1404-15. Epub 2013 Sep 24.

1Clovis Oncology Inc., San Francisco, California; 2Celgene Avilomics Research, Bedford, Massachusetts; 3Division of Hematology-Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; 4Mouse Cancer Genetics Program; and 5Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, Maryland.

View Article and Find Full Text PDF
December 2013

Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer.

Authors:
Thomas C Harding Li Long Servando Palencia Hongbing Zhang Ali Sadra Kevin Hestir Namrata Patil Anita Levin Amy W Hsu Deborah Charych Thomas Brennan James Zanghi Robert Halenbeck Shannon A Marshall Minmin Qin Stephen K Doberstein Diane Hollenbaugh W Michael Kavanaugh Lewis T Williams Kevin P Baker

Sci Transl Med 2013 Mar;5(178):178ra39

Five Prime Therapeutics Inc., South San Francisco, CA 94080-7047, USA.

View Article and Find Full Text PDF
March 2013

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

Authors:
Alfons J M van den Eertwegh Jurjen Versluis H Pieter van den Berg Saskia J A M Santegoets R Jeroen A van Moorselaar Tim M van der Sluis Helen E Gall Thomas C Harding Karin Jooss Israel Lowy Herbert M Pinedo Rik J Scheper Anita G M Stam B Mary E von Blomberg Tanja D de Gruijl Kristen Hege Natalie Sacks Winald R Gerritsen

Lancet Oncol 2012 May 10;13(5):509-17. Epub 2012 Feb 10.

Department of Medical Oncology, VU University Medical Centre, Amsterdam, Netherlands.

View Article and Find Full Text PDF
May 2012

Antibody responses to galectin-8, TARP and TRAP1 in prostate cancer patients treated with a GM-CSF-secreting cellular immunotherapy.

Authors:
Minh C Nguyen Guang Huan Tu Kathryn E Koprivnikar Melissa Gonzalez-Edick Karin U Jooss Thomas C Harding

Cancer Immunol Immunother 2010 Sep 25;59(9):1313-23. Epub 2010 May 25.

Cell Genesys Inc., South San Francisco, CA 94080, USA.

View Article and Find Full Text PDF
September 2010

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Authors:
B Douglas Smith Yvette L Kasamon Jeanne Kowalski Christopher Gocke Kathleen Murphy Carole B Miller Elizabeth Garrett-Mayer Hua-Ling Tsai Lu Qin Christina Chia Barbara Biedrzycki Thomas C Harding Guang Haun Tu Richard Jones Kristen Hege Hyam I Levitsky

Clin Cancer Res 2010 Jan;16(1):338-47

Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and St Agnes Hospital, Baltimore, Maryland 21231, USA.

View Article and Find Full Text PDF
January 2010

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo.

Authors:
Jianmin Fang Saili Yi Andrew Simmons Guang Huan Tu Minh Nguyen Thomas C Harding Melinda VanRoey Karin Jooss

Mol Ther 2007 Jun 20;15(6):1153-9. Epub 2007 Mar 20.

Department of Preclinical Oncology and Immunology, Cell Genesys, Inc., South San Francisco, California 94080, USA.

View Article and Find Full Text PDF
June 2007